OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine.Expert Opin Biol Ther 2010; 10(2):289-98EO
IMPORTANCE OF THE FIELD
Migraine is a highly prevalent disorder with the potential to progress into a chronic disease. The disability and health effects associated with frequent episodes of migraine underscore the value of preventive pharmacotherapy.
AREAS COVERED IN THIS REVIEW
OnabotulinumtoxinA has been studied as a migraine preventive in numerous clinical trials and in a variety of subpopulations with migraine. Overall, results from the clinical trials are mixed. However, the largest and most recent parallel studies (n = 1330) conducted on subjects with chronic migraine achieved statistically significant efficacy on numerous endpoints including the primary endpoint of reduction of headache days.
WHAT THE READER WILL GAIN
This article reviews several clinical studies using onabotulinumtoxinA in migraine prevention and highlights some of the inherent difficulties defining study endpoints and outcomes that are relevant to clinician, patients, and regulatory agencies.